

1 **Running Title:** SARS-CoV-2 neutralization in Chilean population

2 **Keywords:** BNT162b2; CoronaVac; AZD1222; COVID-19; SARS-CoV-2; Neutralizing
3 antibodies; Chile; Santiago; Talca; Coquimbo; La Serena; coronavirus disease; general
4 population; cross sectional design; respiratory infections; severe acute respiratory syndrome
5 coronavirus 2; vaccine-preventable diseases; viruses.

6 **Title:** SARS-CoV-2 neutralizing antibodies in Chile after a vaccination campaign with five
7 different schemes

8 **Authors:** Ximena Aguilera, Juan Hormazabal, Cecilia Vial, Lina Jimena Cortes, Claudia
9 Gonzalez, Paola Rubilar, Mauricio Apablaza, Muriel Ramirez-Santana, Gloria Icaza, Loreto
10 Nuñez-Franz, Carla Castillo-Laborde, Carolina Ramirez-Riffo, Claudia Perez, Ruben Quezada-
11 Gate, Macarena Said, Pablo Vial.

12 **Author Affiliations:**

13 Universidad del Desarrollo, Santiago, Chile (Ximena Aguilera, Juan Hormazabal, Cecilia Vial,
14 Lina Jimena Cortes, Claudia Gonzalez, Mauricio Apablaza, Paola Rubilar, Carla Castillo-
15 Laborde, Carolina Ramirez, Claudia Perez, Pablo Vial).

16 Universidad Católica del Norte, Coquimbo, Chile (Muriel Ramirez-Santana, Ruben Quezada-
17 Gaete)

18 Universidad de Talca, Talca, Chile (Gloria Icaza, Loreto Nuñez-Franz, Macarena Said)

19 Clínica Alemana de Santiago, Chile (Pablo Vial)

20 **Word count:**

21 Abstract: 50 words

22 Text: 1,197 words

23 **Abstract**

24 Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2
25 vaccine campaign, which combines technologies and heterologous boosters. In 120 randomly
26 selected seropositive individuals from a population-based study, we conclude that the booster
27 dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly
28 improve nAbs response.

29 **Introduction:**

30 The SARS-CoV-2 pandemic has unprecedented challenges for its global, regional, and national
31 control. The continuous emergence of the SARS-CoV-2 variants, jointly with the waning
32 antibody titers from natural and vaccine-induced immunity, generates scenarios that maintain
33 population susceptibility and risk of outbreaks (1,2). Chile is not the exception, presenting one
34 of the worst outbreaks in the world by mid-2020, but also with a globally successful vaccine
35 campaign. The Chilean vaccination strategy combined different vaccine technologies and
36 heterologous boosters (3). We aim to compare the various vaccination schemes, using the
37 presence of neutralizing antibodies (nAbs) as a correlate of immune protection against SARS-
38 CoV-2 (4,5).

39 The Ethics Committees of the Universities el Desarrollo and Talca and the Facultad de Medicina
40 of the Universidad Católica del Norte approved the study protocols. Informed consent was
41 obtained from all subjects, if subjects are under 18, from a parent or legal guardian.

42 **The study:**

43 Serum neutralization capacity was measured using a pseudotyped vesicular stomatitis virus with
44 a sequence encoding the enhanced green fluorescent protein as a reporter gene (VSV-GFP-Spike
45 SARS-CoV-2 original Wuhan strain) kindly donated by Dr. Kartik Chandran (6). Samples tested

46 came from individuals enrolled in a population-based SARS-CoV-2 seroprevalence study
47 performed by the same research team (7–9). In November 2021, we collected 2,198 serum
48 samples from seven-year-old and older people, finding 97.3% of seropositivity. We used six
49 groups of positive samples according to natural infection history and the five most frequent
50 vaccination schemes, selecting randomly 20 individuals from each group (Table 1).
51 The amount of nAbs response was measured as the inhibitory concentration where 50% of the
52 viral entrance is inhibited (IC₅₀). IC₅₀ was calculated for each serum by measuring the viral
53 entrance of the VSV-GFP-Spike SARS-CoV-2 pseudotype capturing the amount of GFP
54 fluorescence in each serum dilution. Briefly, serum serial dilutions from 1/50 to 1/51200 were
55 incubated with VSV-GFP-Spike SARS-CoV-2 pseudovirus for 30 minutes, and then VEROE6
56 cells (ATCC) were infected with this virus. After 20 hours, cells were washed, fixed in 4%
57 paraformaldehyde, and GFP intensity was measured in a Cytation 3 (BioTeK). The resulting
58 curve of each serum was analyzed through a dose-response nonlinear regression in Prism v9
59 Software (Graphpad) to calculate the IC₅₀.
60 We found nAbs response in 82.5% of the subjects, without significant differences by sex or age.
61 The presence of nAbs is significantly higher in people with booster doses and non-smokers.
62 Also, it varies according to vaccine platform used (inactivated, mRNA or viral vector
63 recombinant) (Table 2).
64 Figure 1 shows the level of neutralizing antibodies represented as median and interquartile
65 values of the IC₅₀ for each study group. In the left panel, when comparing nAbs levels, the
66 group with only a basal immunization scheme has nAbs levels similar to that of the naturally
67 infected patients (p value=0.8425). In contrast, individuals who received a booster dose have a
68 significantly higher level of nAbs compared to the other two groups.

69 On the right panel of Figure 1, analyzing the schemes by the different vaccines used, it is
70 observed that the PPP scheme elicited the highest median nAbs response, without significant
71 differences with the heterologous CCP scheme, but higher than the CCO scheme. On the other
72 hand, all three booster schemes produced significantly higher nAbs levels than the natural
73 infection group and the two basal schemes studied (CC and PP). Among the basal schemes, there
74 are also significantly higher nAbs levels for the scheme with mRNA vaccines (PP) compared to
75 inactivated vaccines (CC).

76 Figure 2 is a scatter plot showing the relationship between nAbs titers and time, using days since
77 the last vaccine dose. It shows the waning of antibody titers for the groups with the basal vaccine
78 scheme, but not for the groups with the booster doses, but also the follow-up was shorter for the
79 latter groups.

80 **Conclusions:**

81 Our results demonstrate that vaccination with a booster dose significantly improves the
82 neutralization of the virus, and this effect may be associated with the relatively lower impact of
83 the circulation of the Delta variant observed in Chile compared to the previous SARS-CoV-2
84 variants in terms of cases, hospitalizations, and deaths (10). By December 2021, 84.1% of the
85 Chilean population had received a basal scheme vaccination and 56.1% a booster dose (10).
86 People with natural infection had a similar level of nAbs compared to people vaccinated with the
87 basal schemes. However, nAbs levels in both groups, natural infection, and basal schemes, were
88 significantly lower than those with booster doses, reinforcing the importance of universal
89 vaccination, regardless of the history of the disease, as a strategy that confers higher protection.
90 Likewise, our results demonstrate the higher immunogenic potency of the mRNA vaccines, both
91 in the basal and the booster dose schemes (5,11,12). Other studies on healthcare workers from

92 Chilean institutions support the higher neutralizing titers triggered by mRNA vaccines' basal
93 scheme (13). A possible explanation might be the loss of antigenic sites in inactivated vaccines
94 which only are exposed on a pre-fusion architectonic state of Spike, which is necessary for
95 infection dynamics (14).

96 Nevertheless, the heterologous booster scheme, combining inactivated and mRNA vaccines
97 (CCP), displayed a heterogeneous response, including 15% of subjects without nAbs; this figure
98 is zero in the other two booster schemes (CCO and PPP), and 10% in those with PP basal
99 scheme. Interestingly, the CCP group is younger than the CCO group (average 44 vs. 69 years
100 old respectively), similar to PPP (average 44 years old), because the Chilean Health Authority
101 restricted the use of ChAdOx1-S recombinant vaccine to people older than 55 years. A possible
102 explanation for the proportion of non-responders with the CCP scheme may be the short time
103 elapsed since the last vaccination. In fact, in 2 of the three subjects without nAbs, the sample
104 collection was before 14 days, and this occurred in just 1 of the 17 nAbs responders. The
105 neutralization analysis detected significant differences according to vaccine technologies not
106 seen in measuring total SARS-CoV-2 antibodies (8). This added value, provided by
107 neutralization studies, allows a deeper understanding of the antibody response to vaccines and
108 natural infection to guide the public health response to the pandemic. Despite high vaccination
109 coverage, we are still susceptible to new variants with the ability to evade the immune response,
110 as was observed with the circulation of Omicron.

111 Finally, we found a lower nAbs response in smokers than non-smokers, consistent with studies
112 suggesting a more inadequate humoral response in smokers (15).

113 The strength of this study includes the analysis of different vaccine technologies. In addition, it is
114 a sample of subjects that comes from a population study and not from specific groups of the

115 population. As for weaknesses, the moderate number of samples analyzed by vaccine technology
116 does not include neutralizing antibodies against different variants of SARS-CoV-2, such as Delta
117 and Omicron. Although previous studies have shown a correlation in neutralization for the
118 different variants of SARS-CoV-2 (13), relevant changes have been detected for those with a
119 greater capacity to evade the immune response.

120 We conclude that the booster dose significantly improves the levels of neutralizing antibodies
121 against SARS-CoV-2, regardless of the vaccination scheme or the levels acquired by natural
122 infection. Also, mRNA vaccine technology is strongly associated with higher neutralizing
123 antibody levels than inactivated virus vaccines.

124

125 **References:**

- 126 1. Magazine N, Zhang T, Wu Y, McGee MC, Veggiani G, Huang W. Mutations and
127 Evolution of the SARS-CoV-2 Spike Protein. *Viruses*. 2022 Mar 19;14(3):640.
- 128 2. Muena NAA, García-Salum T, Pardo-Roa C, Jos E Avenda~ M, Serrano EF, Levican J, et
129 al. Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2
130 vaccines in naïve and previously infected individuals. 2022; Available from:
131 <https://doi.org/10.1016/j.>
- 132 3. Aguilera X, Mundt AP, Araos R, Weitzel T. The story behind Chile's rapid rollout of
133 COVID-19 vaccination. *Travel Med Infect Dis*. 2021;42(May):5–7.
- 134 4. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
135 Neutralizing antibody levels are highly predictive of immune protection from
136 symptomatic SARS-CoV-2 infection. *Nat Med [Internet]*. 2021;27(7):1205–11. Available
137 from: <http://dx.doi.org/10.1038/s41591-021-01377-8>

- 138 5. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al.
139 Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine*
140 [Internet]. 2021;39(32):4423–8. Available from:
141 <https://doi.org/10.1016/j.vaccine.2021.05.063>
- 142 6. Dieterle ME, Haslwanter D, Bortz RH, Wirchnianski AS, Lasso G, Vergnolle O, et al. A
143 Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-
144 Mediated Cell Entry and Its Inhibition. *Cell Host Microbe* [Internet]. 2020;28(3):486-
145 496.e6. Available from: <https://doi.org/10.1016/j.chom.2020.06.020>
- 146 7. Vial P, González C, Icaza G, Ramirez-Santana M, Quezada-Gaete R, Núñez-Franz L, et
147 al. Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three
148 urban centers of Chile. *BMC Infect Dis*. 2022;22(1).
- 149 8. Aguilera X, Gonzalez C, Apablaza M, Rubilar P, Icaza G, Ramirez-Santana M, et al.
150 Immunization and SARS-CoV-2 antibodies seroprevalence in a country with high
151 vaccination coverage: Lessons from Chile. *Res Sq* [Internet]. 2022; Available from:
152 <https://www.researchsquare.com/article/rs-1548211/v1>
- 153 9. Bergeri I, Ware H, Subissi L, Nardone A, Lewis HC, Li Z, et al. Global epidemiology of
154 SARS-CoV-2 infection: a systematic review and meta- analysis of standardized
155 population-based seroprevalence studies, Jan 2020-Dec 2021. *medRxiv* [Internet]. 2022;
156 Available from: <https://www.medrxiv.org/content/10.1101/2021.12.14.21267791v2>
- 157 10. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19). Our
158 World Data [Internet]. 2020 Mar 5 [cited 2021 Apr 26]; Available from:
159 <https://ourworldindata.org/coronavirus>
- 160 11. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a

- 161 third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in
162 Israel: an observational study. *Lancet*. 2021;398(10316):2093–100.
- 163 12. Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and
164 immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two
165 doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded,
166 multicentre, randomised, controlled, phase 2 trial. *Lancet*. 2021;398(10318):2258–76.
- 167 13. Acevedo ML, Gaete-Argel A, Alonso-Palomares L, de Oca MM, Bustamante A, Gaggero
168 A, et al. Differential neutralizing antibody responses elicited by CoronaVac and
169 BNT162b2 against SARS-CoV-2 Lambda in Chile. *Nat Microbiol*. 2022;7(4):524–9.
- 170 14. Liu C, Mendonça L, Yang Y, Gao Y, Shen C, Liu J, et al. The Architecture of Inactivated
171 SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-EM and Cryo-ET. *Structure*.
172 2020;28(11):1218-1224.e4.
- 173 15. Ferrara P, Gianfredi V, Tomaselli V, Polosa R. The Effect of Smoking on Humoral
174 Response to COVID-19 Vaccines: A Systematic Review of Epidemiological Studies.
175 *Vaccines*. 2022;10(2):1–16.
176

177

Table 1. Vaccination schemes and sample distribution, Chile 2021

Vaccine scheme acronym	Description	N
CC (CoronaVac CoronaVac)	Basal scheme = two doses of Sinovac's CoronaVac	20
PP (Pfizer Pfizer)	Basal scheme = two doses of BNT162b2	20
CCO (CC plus Oxford AstraZeneca)	Basal CC plus booster with ChAdOx1-S (heterologous)	20
CCP (CC plus Pfizer)	Basal CC plus booster with BNT162b2 (heterologous)	20
PPP (Triple Pfizer)	Basal PP plus booster with BNT162b2	20
Natural infection	Non-vaccinated, but seropositive (Natural Infection)	20

178

179

180 **Table 2. Presence of Neutralizing Antibodies against SARS-CoV-2 among**
 181 **seropositive individuals according to selected variables, Chile November 2021**

Variable		n	Median nAbs (p25-p75) §	Positive Ab response	Prevalence (%)	p-value
Total		120	730.7 (63.4-7757.1)	99	82.5%	.
Sex	Male	43	485.4 (71.6-6939.6)	37	86.0%	0.31
	Female	77	1640.2 (42.3-8333.3)	62	80.5%	.
Age group	7-19	16	336.1 (124.1-1084.1)	15	93.8%	0.20
	20-59	81	668.9 (38.1-11076.7)	63	77.8%	.
	60+	23	2637.1 (558-6939.6)	21	91.3%	.
COVID-19 diagnosis	No	108	698.9 (55.5-7283.7)	87	80.6%	0.09
	Yes	12	2970.9 (141-12809.6)	12	100.0%	.
Presence of symptoms*	No	74	2293.3 (87.3-7627.8)	62	83.8%	0.41
	Yes	46	356.2 (40.4-9615.4)	37	80.4%	.
Comorbidity†	No	65	668.9 (60.8-6583.3)	54	83.1%	0.52
	Yes	55	732.6 (66-9578.5)	45	81.8%	.
Tobacco	No	83	800.6 (86.8-5274.3)	73	88.0%	0.02
	Yes	37	558 (10-11611.7)	26	70.3%	.
Vaccine	No	20	75.4 (18-356.5)	15	75.0%	0.25
	At least one dose	100	2522.4 (98.8-9845.5)	84	84.0%	.
Vaccine doses	Basal scheme	40	80.8 (10-700.7)	27	67.5%	0.00
	Booster	60	6172.3 (2522.4-12346.1)	57	95.0%	.
Vaccine scheme‡	CC	20	10 (10-132.2)	9	45.0%	0.00
	PP	20	292.9 (68.8-1614)	18	90.0%	.
	CCO	20	3305.1 (1184.5-7636.5)	20	100.0%	.
	CCP	20	7105.5 (4456.6-24035.9)	17	85.0%	.
	PPP	20	9597 (4884.6-18837.4)	20	100.0%	.
	Natural infection	20	75.4 (18-356.5)	15	75.0%	.

182 *COVID-19 compatible symptoms including fever, cough, odynophagia, dyspnea, headache, myalgia, chest pain, abdominal pain,
 183 diarrhea, fatigue, anosmia and dysgeusia.

184 †Comorbidities including overweight and obesity, diabetes, high blood pressure, heart diseases, chronic respiratory diseases
 185 (asthma, COPD), cancer and hypothyroidism.

186 ‡Vaccine scheme acronym description in Table 1.

187 §Antibody levels correspond to the reciprocal of the IC50.

188

189 **Figure legends:**

190 Figure 1: All samples were plotted as individuals points and graphed the median and interquartile for both
191 panels. Left panel shows a comparison of nAbs titers between natural infection (n=20), two dose
192 schemes (n=40), and booster dose (n=60). The right panel shows a comparison of nABs between the
193 different vaccination schemes: CC (CoronaVac CoronaVac), PP (Pfizer Pfizer), CCO (CC plus Oxford
194 AstraZeneca), CCP (CC plus Pfizer), PPP (Triple Pfizer), with n=20 for each group. The statistical
195 differences were performed with kruskal-Wallis test, and a p-value < 0.05.

196

197 **Acknowledgments**

198 This research has been supported by WHO Unity Studies, a global seroepidemiological
199 standardization initiative, with funding to WHO by the COVID-19 Solidarity Response Fund and
200 the German Federal Ministry of Health (BMG) COVID-19 Research and Development Fund.

201 We thank K. Chandran for provision of a seed stock of VSV-GFP-Spike SARS-CoV-2
202 pseudotype.

203 **Disclaimer**

204 The opinions expressed by authors contributing to this journal do not necessarily reflect the
205 opinions of the Centers for Diseases Control and Prevention or the Institutions with which the
206 authors are affiliated.

207 **Conflicts of Interest**

208 The authors declare that they have no competing interests

209 **Biographical Sketch**

210 Dr. Ximena Aguilera is full professor of Public Health and Director of the Center of
211 Epidemiology and Health Policy at the Universidad del Desarrollo, Santiago, Chile. Previously,

212 she was Senior advisor on Communicable Diseases in the Pan American Health Organization
213 (PAHO) in Washington DC. Earlier, she was head of Health Planning Division and head of the
214 Department of Epidemiology for the Chilean Ministry of Health. Her interests include applied
215 epidemiology to infectious diseases, global health, and health systems.

216 **Address for correspondence:**

217 Corresponding author: Ximena Aguilera MD MPH
218 Centro de Epidemiología y Políticas de Salud,
219 Facultad de Medicina Clínica Alemana Universidad del Desarrollo.
220 Av. Plaza #680, San Carlos de Apoquindo, Las Condes. Santiago, Chile.
221 Postal code: 7610658
222 e-mail xaguilera@udd.cl
223 phone number: (562) 223279308



